---
title: "CONDUIT PHARMACEUTICALS INC C/WTS 22/09/2028(TO PUR COM) | 10-Q: FY2025 Q2 EPS: USD -5.46"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253103153.md"
datetime: "2025-08-14T21:02:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253103153.md)
  - [en](https://longbridge.com/en/news/253103153.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253103153.md)
generator: "portal-rs"
---

# CONDUIT PHARMACEUTICALS INC C/WTS 22/09/2028(TO PUR COM) | 10-Q: FY2025 Q2 EPS: USD -5.46

EPS: As of FY2025 Q2, the actual value is USD -5.46.

### Segment Revenue

-   **Research and Development Expenses**: $1.8 million for the three months ended June 30, 2025, compared to $25,000 for the same period in 2024. For the six months ended June 30, 2025, expenses were $2.8 million, compared to $153,000 for the same period in 2024.

### Operational Metrics

-   **Net Loss**: $6.0 million for the three months ended June 30, 2025, compared to $5.4 million for the same period in 2024. For the six months ended June 30, 2025, net loss was $10.8 million, compared to $8.9 million for the same period in 2024.
-   **General and Administrative Expenses**: $3.1 million for the three months ended June 30, 2025, compared to $3.1 million for the same period in 2024. For the six months ended June 30, 2025, expenses were $5.8 million, compared to $5.9 million for the same period in 2024.

### Cash Flow

-   **Operating Cash Flow**: Net cash used in operating activities was $6.5 million for the six months ended June 30, 2025, compared to $3.9 million for the same period in 2024.
-   **Investing Cash Flow**: Net cash used in investing activities was $405,000 for the six months ended June 30, 2025, compared to $224,000 for the same period in 2024.
-   **Financing Cash Flow**: Net cash provided by financing activities was $9.7 million for the six months ended June 30, 2025, compared to $113,000 for the same period in 2024.

### Unique Metrics

-   **Convertible Notes Payable**: As of June 30, 2025, there was approximately $3.6 million in outstanding principal and interest remaining on the A.G.P. Convertible Note.
-   **Warrants**: The Company issued 1,908 A.G.P. 2024 Warrants to purchase shares of Common Stock at an exercise price of $157.20 per share.

### Future Outlook and Strategy

-   **Core Business Focus**: CDT Equity Inc. plans to continue leveraging artificial intelligence and solid-form chemistry to enhance and advance high-potential therapeutic assets. The company aims to unlock the value of clinical-stage compounds, particularly those deprioritized by larger pharmaceutical companies, and extend patent life by up to 20 years through advanced co-crystallization and solid-form technologies.
-   **Non-Core Business**: The company is exploring a cryptocurrency treasury reserve strategy as part of a diversified capital management approach. This strategy aims to present both strategic and financial benefits by gaining long-term exposure to digital assets.
-   **Priority**: CDT Equity Inc. will focus on high-leverage development strategies, avoiding the cost burden of late-stage clinical trials, and will seek third-party license deals following successful pre-clinical trials.

### Related Stocks

- [CDTTW.US](https://longbridge.com/en/quote/CDTTW.US.md)

## Related News & Research

- [Does Instacart’s New Exclusivity And Category Expansions Reshape The Bull Case For Maplebear (CART)?](https://longbridge.com/en/news/298119807.md)
- [Why CF Industries (CF) Is Up 6.0% After Blue Ammonia JV and Leadership Transition News](https://longbridge.com/en/news/298114954.md)
- [Is Camtek (CAMT) Options Frenzy Quietly Reframing Its Near‑Term Earnings Story?](https://longbridge.com/en/news/298114664.md)
- [Is Huntington Bancshares (HBAN) Undervalued As Its Growth Narrative Expands?](https://longbridge.com/en/news/298114667.md)
- [Elon Can’t Build His Empire Alone](https://longbridge.com/en/news/298114289.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**